Steven Burke
Vermögen: 502 783 $ am 31.08.2026
Vermögen: 502 783 $ am 31.08.2026
Steven K.
Burke is currently Director at LeukoSight, Inc. and AbFero Pharmaceuticals, Inc. Since 2019, Dr. Burke has been Chief Medical, Research & Development Officer at Akebia Therapeutics, Inc. Formerly, Dr. Burke was Medical Director & VP-Clinical Research at GelTex Pharmaceuticals, Inc. from 1994 to 2001, Associate Director-Clinical Research at Glaxo, Inc., Senior VP-Medical and Regulatory Affairs at Genzyme Corp.
in 2011, Chief Medical Officer & Senior Vice President at Proteon Therapeutics, Inc. from 2006 to 2019, and Chief Medical Officer at Protara Therapeutics, Inc. Education includes a doctorate from Weill Cornell Medical College and undergraduate studies at Harvard College.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2026 | 547.098 ( 0,2 % ) | 502 783 $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| AKEBIA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 17.06.2019 |
LeukoSight, Inc.
LeukoSight, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics to treat autoimmune and inflammatory diseases | Direktor/Vorstandsmitglied | - |
AbFero Pharmaceuticals, Inc.
AbFero Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oral iron chelators for the treatment of diseases of iron overload | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
| PROTARA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2019 |
GelTex Pharmaceuticals, Inc.
GelTex Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops non-absorbed, polymer-based pharmaceuticals | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2001 |
| PROTARA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Glaxo, Inc. | Corporate Officer/Principal | - |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Technik-/Wissenschafts-/F&E-Leiter | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
GelTex Pharmaceuticals, Inc.
GelTex Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops non-absorbed, polymer-based pharmaceuticals | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Proteon Therapeutics, Inc.
Proteon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops pharmaceuticals products for patients with renal and vascular disease | Health Technology |
Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs for kidney diseases | Health Technology |
Glaxo, Inc. | |
LeukoSight, Inc.
LeukoSight, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics to treat autoimmune and inflammatory diseases | Health Technology |
Weill Cornell Medical College
Weill Cornell Medical College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard College
Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AbFero Pharmaceuticals, Inc.
AbFero Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oral iron chelators for the treatment of diseases of iron overload | Health Technology |
Protara Therapeutics, Inc.
Protara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen